Best Peptides for Sexual Health
Peptides studied for sexual function, libido, and reproductive health
Sexual health peptides work through diverse neuroendocrine pathways. PT-141 (Bremelanotide) is the most notable — it's FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides with regulatory approval for a sexual health indication.
Other peptides in this space include Kisspeptin (a key regulator of the reproductive axis), Oxytocin (the "bonding hormone"), and Gonadorelin (a GnRH agonist used to support testosterone production during hormonal therapies).
Sexual Health Peptides (1)
Frequently Asked Questions
Yes. PT-141 (Bremelanotide), marketed as Vyleesi, is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin-4 receptors in the brain, which differs from the vascular mechanism of PDE5 inhibitors like Viagra.
PT-141 works centrally in the brain through melanocortin receptors to increase sexual desire, while Viagra (sildenafil) works peripherally by increasing blood flow through PDE5 inhibition. PT-141 affects desire/arousal at the neurological level; Viagra affects the physical mechanics of erection.
Kisspeptin stimulates GnRH release from the hypothalamus, which triggers LH and FSH release from the pituitary, ultimately stimulating testosterone production. Clinical studies have shown acute kisspeptin administration increases testosterone levels. It's being researched as a potential diagnostic and therapeutic tool for reproductive disorders.
The most common side effect is nausea, reported in approximately 40% of clinical trial participants. Other side effects include facial flushing, headache, and injection-site reactions. PT-141 may transiently elevate blood pressure, so individuals with heart disease or unmanaged hypertension should avoid it. Unlike Melanotan II (from which it was derived), PT-141 does not cause significant skin darkening.
In clinical trials, 34% of men in the PT-141 group reported significantly improved erectile function compared to 9% on placebo. However, PT-141 is FDA-approved only for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its use in men for erectile dysfunction is off-label. PT-141 works through desire and arousal pathways in the brain, not through the vascular mechanism of PDE5 inhibitors like Viagra.
Both act on melanocortin receptors, but PT-141 (Bremelanotide) is a more selective melanocortin-4 receptor agonist specifically developed for sexual function. Melanotan II is a broader melanocortin agonist that affects skin pigmentation, appetite, and sexual function simultaneously. PT-141 is FDA-approved; Melanotan II is not approved anywhere and carries more side effects including skin darkening, nausea, and mole changes.
Oxytocin, sometimes called the bonding hormone, has been studied intranasally for effects on social bonding, trust, and pair bonding. While it plays a physiological role in sexual response and emotional attachment, clinical evidence for oxytocin as a standalone libido enhancer is limited. It is more commonly discussed in the context of relationship bonding and social cognition research than as a direct sexual performance peptide.